Profile data is unavailable for this security.
About the company
Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
- Revenue in EUR (TTM)60.80m
- Net income in EUR63.90m
- Incorporated2012
- Employees239.00
- LocationFormycon AGFraunhoferstrasse 15MARTINSRIED 82152GermanyDEU
- Phone+49 89 864667100
- Fax+49 89 864667110
- Websitehttps://www.formycon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puretech Health PLC | 446.91k | -78.75m | 468.53m | 90.00 | -- | 1.55 | -- | 1,048.39 | -0.239 | -0.239 | 0.0014 | 1.05 | 0.0007 | -- | 0.2252 | 4,131.56 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Abivax SA | 0.00 | -177.43m | 519.02m | 62.00 | -- | 4.08 | -- | -- | -3.20 | -3.20 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -77.89 | -65.49 | -107.73 | -97.67 | -- | -- | -- | -- | -- | -110.67 | 0.4334 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Oxford BioMedica plc | 116.92m | -170.69m | 525.14m | 834.00 | -- | 6.56 | -- | 4.49 | -1.44 | -1.44 | 0.9642 | 0.6292 | 0.3012 | 4.09 | 4.21 | 136,252.10 | -51.98 | -19.60 | -66.85 | -24.68 | 36.74 | 50.74 | -172.59 | -44.38 | 2.07 | -12.47 | 0.6077 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Basilea Pharmaceutica AG Allschwil | 160.45m | -702.00k | 574.99m | 156.00 | -- | 29.28 | 465.19 | 3.58 | -0.2814 | -0.2814 | 11.54 | 1.38 | 0.7118 | 1.22 | 4.40 | 1,013,755.00 | -0.3114 | -1.86 | -0.4156 | -2.99 | 76.57 | 83.45 | -0.4375 | -2.99 | 3.27 | -1.38 | 0.8508 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Philogen SpA | 2.28m | -29.35m | 583.40m | 174.00 | -- | 10.60 | -- | 255.43 | -0.7301 | -0.7301 | 0.0568 | 1.88 | 0.0191 | 5.55 | 1.57 | 14,275.00 | -24.49 | -7.32 | -27.75 | -8.36 | -564.19 | 32.04 | -1,285.03 | -58.66 | 5.02 | -- | 0.155 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Formycon AG | 60.80m | 63.90m | 821.05m | 239.00 | 11.63 | 1.42 | 12.45 | 13.50 | 4.00 | 4.00 | 3.64 | 32.64 | 0.0654 | 34.46 | 1.55 | 255,462.20 | 6.87 | 5.87 | 7.37 | 6.33 | 12.46 | 28.54 | 105.09 | 39.76 | 2.06 | -- | 0.0185 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| Kuros Biosciences AG | 56.57m | -9.57m | 906.59m | 80.00 | -- | 13.69 | -- | 16.03 | -0.2295 | -0.2295 | 1.73 | 1.64 | 0.6755 | 1.95 | 7.89 | 656,775.00 | -11.42 | -13.47 | -13.53 | -14.84 | 79.13 | 78.73 | -16.91 | -81.48 | 2.17 | -- | 0.0847 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| BioArctic AB | 14.43m | -20.10m | 1.18bn | 104.00 | -- | 17.84 | -- | 81.71 | -2.64 | -2.64 | 1.89 | 10.39 | 0.1431 | -- | -- | 1,899,330.00 | -19.94 | 2.24 | -22.13 | 2.56 | 80.72 | 86.52 | -139.32 | 9.76 | -- | -- | 0.0578 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
Data as of Nov 22 2024. Currency figures normalised to Formycon AG's reporting currency: Euro EUR
9.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Active Ownership Corp SARLas of 31 Dec 2023 | 1.07m | 6.09% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 160.50k | 0.91% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 30 Sep 2024 | 140.39k | 0.80% |
| Plutos Verm�gensverwaltung AGas of 31 Mar 2024 | 100.00k | 0.57% |
| Lupus alpha Asset Management AGas of 30 Jun 2024 | 61.00k | 0.35% |
| Paladin Asset Management Investmentaktiengesellschaft TGVas of 30 Jun 2024 | 60.00k | 0.34% |
| MPPM Manfred Piontke Portfolio Management e.K.as of 31 Mar 2024 | 44.00k | 0.25% |
| TBF Global Asset Management GmbHas of 30 Sep 2024 | 39.55k | 0.22% |
| Cr�dit Mutuel Asset Management SAas of 29 Dec 2023 | 36.48k | 0.21% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 32.66k | 0.19% |
More ▼
Data from 31 Mar 2024 - 05 Nov 2024Source: FactSet Research Systems Inc.
